Company

AVEROA SAS

French public company (société anonyme simplifié)

Share capital: 1.329.799€

Trade and Companies Register number: 908 469 406 R.C.S. Grenoble

Address: 11 Avenue Paul Verlaine, 38100 Grenoble, France

Contact: info@averoa-pharma.com

Website hosting & publishing manager

AVEROA SAS

R.C.S. 908 469 406 Grenoble

11 Avenue Paul Verlaine,

38100 Grenoble, France

Intellectual Property

This website and its content (including its overall layout as well as any text, photographs, images, trademarks, logos, videos, or other elements of the website) are the property of Averoa or have been licensed to Averoa. Any reproduction, adaptation, translation, whether in full or in part, of this website is strictly prohibited unless prior and written consent of Averoa. No hypertext link to the website or to any part thereof may be established without the prior written consent of Averoa.

 

Personal data protection

Your personal data are collected and used for information and communication only. In accordance with the Data Protection Act of January 6, 1978 (loi n°78-17 du 6 janvier 1978 relative à l’Informatique et aux Libertés), you have access to your personal data and you may request modification to or deletion of such data by e-mail at info@averoa-pharma.com or by mail to Averoa, 11 Avenue Paul Verlaine, 38100 Grenoble, France.

Dr Luc-André Granier

President & CEO - Medical Director

Co-founder of Advicenne in 2007 and Panntherapi in 2020, he is an expert in the clinical development of innovative products for pharmaceutical and biotech industry. He has conducted many clinical studies and has successfully conducted numerous drug development programs in the field of the central nervous system (CNS) and kidney diseases. In particular, he successfully conducted the proof-of-concept study of the « Blockbuster » duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. His long history of interactions with the U.S. FDA and European (EMA) regulatory agencies provides Averoa with a strategic regulatory vision that is essential to its development.